More cost-effectiveness studies evaluating bispecific antibody or chimeric antigen receptor T-cell therapies are necessary for enhancing care in myeloma and lymphoma.
Sabarish Ayyappan, MD
Advertisement
Sabarish Ayyappan, MD, has been the Medical Director of Hematologic Malignancies at City of Hope Cancer Centers, Atlanta, since 2023. Here he has been leading their hematologic malignancy program with the aim of establishing an additional program for bone marrow transplants.
Articles by Sabarish Ayyappan, MD
Therapy timing, patient factors, and emerging combination interventions are guiding treatment decisions in multiple myeloma and lymphoma.
In the wake of novel bispecific and chimeric antigen receptor T-cell therapies for various cancers, geography still plays a big role in patients' abilities to receive such treatments.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
2025 Nobel Prize in Medicine Honors Discoveries Behind Regulatory T Cells
2
Amgen Direct-to-Patient Program Aims to Expand Access to Evolocumab Amid US Drug Pricing Reforms
3
FDA Expands Roflumilast Use for Atopic Dermatitis to Children Aged 2 to 5 Years
4
Mediterranean Diet Improves Psoriasis Severity, Study Finds
5
